ArticlePloS one2012
Comparison of microarray platforms for measuring differential microRNA expression in paired normal/cancer colon tissues.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 53 citations in OpenAlex.
- Discovery and Validation of Serum MicroRNAs as Early Diagnostic Biomarkers for Prostate Cancer in Chinese Population.BioMed research international · 2019Trial
- MicroRNAs as clinical tools for diagnosis, prognosis, and therapy in prostate cancer.Translational oncology · 2023Article
- Integrated analysis of miRNA-mRNA interaction in pediatric dilated cardiomyopathy.Pediatric research · 2022Article
- Bringing MicroRNAs to Light: Methods for MicroRNA Quantification and Visualization in Live Cells.Frontiers in bioengineering and biotechnology · 2020Review
- Effect of the miR-96-5p inhibitor and mimic on the migration and invasion of the SW480-7 colorectal cancer cell line.Oncology letters · 2019Article
- EPA significantly improves anti-EGFR targeted therapy by regulating miR-378 expression in colorectal cancer.Oncology letters · 2018Article
- Selection and Application of Tissue microRNAs for Nonendoscopic Diagnosis of Barrett's Esophagus.Gastroenterology · 2018Article
- MicroRNA expression profiling for the prediction of resistance to neoadjuvant radiochemotherapy in squamous cell carcinoma of the esophagus.Journal of translational medicine · 2018Article
- Association of miR-548c-5p, miR-7-5p, miR-210-3p, miR-128-3p with recurrence in systemically untreated breast cancer.Oncotarget · 2018Article
- Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer.PloS one · 2018Article
- MicroRNAs as biomarkers for liver injury: Current knowledge, challenges and future prospects.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2017Review
- Article
- Clinical value of integrated-signature miRNAs in colorectal cancer: miRNA expression profiling analysis and experimental validation.Oncotarget · 2015Article
- miR-30e* is an independent subtype-specific prognostic marker in breast cancer.British journal of cancer · 2015Article
- MicroRNA-378-5p suppresses cell proliferation and induces apoptosis in colorectal cancer cells by targeting BRAF.Cancer cell international · 2015Article
- Challenges in using circulating miRNAs as cancer biomarkers.BioMed research international · 2015Review
- Micro-RNA expression in hypoplastic left heart syndrome.Journal of cardiac failure · 2015Article
- Interleukin 21 Controls mRNA and MicroRNA Expression in CD40-Activated Chronic Lymphocytic Leukemia Cells.PloS one · 2015Article
- MicroRNAs as lung cancer biomarkers.World journal of clinical oncology · 2014Review
- Differential expression of miRNAs in colon cancer between African and Caucasian Americans: implications for cancer racial health disparities.International journal of oncology · 2014Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroarray technology applied to microRNA (miRNA) profiling is a promising tool in many research fields; nevertheless, independent studies characterizing the same pathology have often reported poorly overlapping results. miRNA analysis methods have only recently been systematically compared but only in few cases using clinical samples. METHODOLOGY/PRINCIPAL
findingsWe investigated the inter-platform reproducibility of four miRNA microarray platforms (Agilent, Exiqon, Illumina, and Miltenyi), comparing nine paired tumor/normal colon tissues. The most concordant and selected discordant miRNAs were further studied by quantitative RT-PCR. Globally, a poor overlap among differentially expressed miRNAs identified by each platform was found. Nevertheless, for eight miRNAs high agreement in differential expression among the four platforms and comparability to qRT-PCR was observed. Furthermore, most of the miRNA sets identified by each platform are coherently enriched in data from the other platforms and the great majority of colon cancer associated miRNA sets derived from the literature were validated in our data, independently from the platform. Computational integration of miRNA and gene expression profiles suggested that anti-correlated predicted target genes of differentially expressed miRNAs are commonly enriched in cancer-related pathways and in genes involved in glycolysis and nutrient transport.
conclusionsTechnical and analytical challenges in measuring miRNAs still remain and further research is required in order to increase consistency between different microarray-based methodologies. However, a better inter-platform agreement was found by looking at miRNA sets instead of single miRNAs and through a miRNAs - gene expression integration approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.